{"id":"maintenance-icotinib","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Rash/dermatitis"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Elevated liver enzymes"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Anorexia"}]},"_chembl":{"chemblId":"CHEMBL2087361","moleculeType":"Small molecule","molecularWeight":"391.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icotinib irreversibly binds to and inhibits EGFR tyrosine kinase, preventing autophosphorylation and downstream signaling cascades that drive cell growth and survival in EGFR-dependent cancers. As a maintenance therapy, it is administered after initial chemotherapy or other treatments to sustain disease control and delay progression in patients with EGFR-mutant lung cancer.","oneSentence":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:49.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT06955325","phase":"PHASE3","title":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-05","conditions":"Non-Small Cell Lung Cancer","enrollment":270},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT01719536","phase":"PHASE3","title":"Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-12","conditions":"NSCLC","enrollment":296},{"nctId":"NCT02889692","phase":"PHASE3","title":"Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2013-03","conditions":"Cancer","enrollment":23},{"nctId":"NCT03151161","phase":"PHASE2","title":"Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-12","conditions":"Lung, Carcinoma","enrollment":118},{"nctId":"NCT01665417","phase":"PHASE4","title":"Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2012-08","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":100},{"nctId":"NCT02430974","phase":"PHASE2","title":"Chemotherapy of NSCLC With or Without Icotinib","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":50},{"nctId":"NCT02103257","phase":"PHASE4","title":"Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-03","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":192},{"nctId":"NCT02407366","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Guangxi Zhuang Autonomous Region","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT02215356","phase":"PHASE2","title":"Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-08","conditions":"Non-small Cell Lung Cancer","enrollment":120},{"nctId":"NCT02194556","phase":"PHASE4","title":"Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2014-07","conditions":"EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gemzar","DDP","Comana, BPI-2009"],"phase":"marketed","status":"active","brandName":"Maintenance icotinib","genericName":"Maintenance icotinib","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icotinib is a small-molecule tyrosine kinase inhibitor that selectively blocks epidermal growth factor receptor (EGFR) signaling to inhibit tumor cell proliferation. Used for Maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}